BACKGROUND AND PURPOSE: Much interest is currently being focused on the anti-nociceptive effects mediated by nicotinic acetylcholine (nACh) receptors, including their location and mechanism of action. The purpose of this study was to elucidate these issues using 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5IA), a nACh receptor agonist, and [(125)I]5IA. EXPERIMENTAL APPROACH: We partially ligated the sciatic nerve of Sprague-Dawley rat to induce neuropathic pain [Seltzer's partial sciatic nerve ligation (PSL) model]. We then examined the changes in nACh receptor density in the CNS using [(125)I]5IA autoradiography and the involvement of nACh receptors in anti-nociceptive effects in the region where changes occurred. KEY RESULTS: Autoradiographic studies showed that the accumulation of [(125)I]5IA and the number of nACh receptors in the thalamus of PSL rats were increased about twofold compared with those in the sham-operated rats. No change was observed in other brain regions. Rats injected in the ventral posterolateral thalamic nucleus (VPL) with 5IA demonstrated a significant and dose-dependent anti-allodynic effect and this effect was completely antagonized by mecamylamine, injected with 5IA, into the VPL. The blockade of nACh receptors in the VPL by mecamylamine decreased by 70% the anti-allodynic effect of 5IA, given i.c.v. Moreover, mecamylamine given intra-VPL by itself, induced significant hyperalgesia. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that the nACh receptors expressed in the VPL play an important role in the anti-allodynic effects produced by exogenous and endogenous agonists.
BACKGROUND AND PURPOSE: Much interest is currently being focused on the anti-nociceptive effects mediated by nicotinic acetylcholine (nACh) receptors, including their location and mechanism of action. The purpose of this study was to elucidate these issues using 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5IA), a nACh receptor agonist, and [(125)I]5IA. EXPERIMENTAL APPROACH: We partially ligated the sciatic nerve of Sprague-Dawley rat to induce neuropathic pain [Seltzer's partial sciatic nerve ligation (PSL) model]. We then examined the changes in nACh receptor density in the CNS using [(125)I]5IA autoradiography and the involvement of nACh receptors in anti-nociceptive effects in the region where changes occurred. KEY RESULTS: Autoradiographic studies showed that the accumulation of [(125)I]5IA and the number of nACh receptors in the thalamus of PSL rats were increased about twofold compared with those in the sham-operated rats. No change was observed in other brain regions. Rats injected in the ventral posterolateral thalamic nucleus (VPL) with 5IA demonstrated a significant and dose-dependent anti-allodynic effect and this effect was completely antagonized by mecamylamine, injected with 5IA, into the VPL. The blockade of nACh receptors in the VPL by mecamylamine decreased by 70% the anti-allodynic effect of 5IA, given i.c.v. Moreover, mecamylamine given intra-VPL by itself, induced significant hyperalgesia. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that the nACh receptors expressed in the VPL play an important role in the anti-allodynic effects produced by exogenous and endogenous agonists.
Authors: D L Donnelly-Roberts; P S Puttfarcken; T A Kuntzweiler; C A Briggs; D J Anderson; J E Campbell; M Piattoni-Kaplan; D G McKenna; J T Wasicak; M W Holladay; M Williams; S P Arneric Journal: J Pharmacol Exp Ther Date: 1998-05 Impact factor: 4.030
Authors: A W Bannon; M W Decker; P Curzon; M J Buckley; D J Kim; R J Radek; J K Lynch; J T Wasicak; N H Lin; W H Arnold; M W Holladay; M Williams; S P Arneric Journal: J Pharmacol Exp Ther Date: 1998-05 Impact factor: 4.030
Authors: Stuart W G Derbyshire; Anthony K P Jones; Ferenc Gyulai; Stuart Clark; David Townsend; Leonard L Firestone Journal: Pain Date: 1997-12 Impact factor: 6.961
Authors: M W Holladay; J T Wasicak; N H Lin; Y He; K B Ryther; A W Bannon; M J Buckley; D J Kim; M W Decker; D J Anderson; J E Campbell; T A Kuntzweiler; D L Donnelly-Roberts; M Piattoni-Kaplan; C A Briggs; M Williams; S P Arneric Journal: J Med Chem Date: 1998-02-12 Impact factor: 7.446
Authors: A W Bannon; M W Decker; M W Holladay; P Curzon; D Donnelly-Roberts; P S Puttfarcken; R S Bitner; A Diaz; A H Dickenson; R D Porsolt; M Williams; S P Arneric Journal: Science Date: 1998-01-02 Impact factor: 47.728
Authors: K Tanaka; Y Fukuuchi; S Gomi; S Takashima; B Mihara; T Shirai; S Nogawa; H Nozaki; E Nagata Journal: Brain Res Bull Date: 1993 Impact factor: 4.077
Authors: David C Perry; Danyan Mao; Allison B Gold; J Michael McIntosh; John C Pezzullo; Kenneth J Kellar Journal: J Pharmacol Exp Ther Date: 2007-04-19 Impact factor: 4.030
Authors: Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj Journal: Neuropharmacology Date: 2021-04-18 Impact factor: 5.273
Authors: Farah Deba; Kara Ramos; Matthew Vannoy; Kemburli Munoz; Lois S Akinola; M Imad Damaj; Ayman K Hamouda Journal: Molecules Date: 2020-06-25 Impact factor: 4.411